RESUMO
Erythropoietin(EPO) is a main growth factor that regulates the erythropoiesis under the physiological conditions and after blood loss. At present, it is one of the special effective clinical drugs for treating anemia due to renal failure, chronic infection, AIDS, tumor and some other causes. However, its short plasma half-life makes more frequent administration, which increases the burden and pain on patients. Therefore, development of long-acting agents is a hot. Continuous erythropoietin receptor activator(CERA) is a third-generation erythropoiesis-stimulating agents(ESA). It has a largely prolonged plasma half-life and extended administration intervals, which are different from other ESAs. This review gives a detail demonstration about the development, molecular structure, biochemical characteristics and the most common adverse effects of CERA, as well as the international attention when CERA works as a doping.